Jonathan MD - Erasca Chairman CoFounder
| ERAS Stock | USD 2.92 0.14 5.04% |
Insider
Jonathan MD is Chairman CoFounder of Erasca Inc
| Age | 52 |
| Address | 3115 Merryfield Row, San Diego, CA, United States, 92121 |
| Phone | 858 465 6511 |
| Web | https://www.erasca.com |
Erasca Management Efficiency
The company has return on total asset (ROA) of (0.1914) % which means that it has lost $0.1914 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.389) %, meaning that it created substantial loss on money invested by shareholders. Erasca's management efficiency ratios could be used to measure how well Erasca manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.33 in 2024. Return On Capital Employed is likely to drop to -0.4 in 2024. Net Tangible Assets is likely to gain to about 497.3 M in 2024, whereas Total Assets are likely to drop slightly above 350.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Paul Manley | Tff Pharmaceuticals | N/A | |
| Kenneth MD | Cue Biopharma | 64 | |
| Susan MS | Eliem Therapeutics | N/A | |
| Kirk Coleman | Tff Pharmaceuticals | 50 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Mark Lappe | Inhibrx | 57 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| TaiWei Ho | In8bio Inc | 47 | |
| Kate Rochlin | In8bio Inc | 42 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| William Ho | In8bio Inc | 45 | |
| Kenneth LaMontagne | In8bio Inc | N/A | |
| DVM MS | Lantern Pharma | N/A | |
| , MBA | Molecular Partners AG | 51 | |
| James JD | Eliem Therapeutics | 58 | |
| Glenn Mattes | Tff Pharmaceuticals | 67 | |
| BS CPA | Inhibrx | 42 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Kishor Bhatia | Lantern Pharma | 69 | |
| Trishna MD | In8bio Inc | 45 | |
| MBA MD | Eliem Therapeutics | 63 | |
Management Performance
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.19 |
Erasca Inc Leadership Team
Elected by the shareholders, the Erasca's board of directors comprises two types of representatives: Erasca inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Erasca. The board's role is to monitor Erasca's management team and ensure that shareholders' interests are well served. Erasca's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Erasca's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Varney, Scientific Development | ||
| Lisa TesvichBonora, Chief Officer | ||
| Nik Chetwyn, VP Operations | ||
| CPA MS, VP Fin | ||
| Wei MD, Chief Officer | ||
| JD Esq, General Secretary | ||
| Esq JD, General Secretary | ||
| Chandra Lovejoy, VP Affairs | ||
| Chandra MS, Chief Officer | ||
| MS CPA, Senior Finance | ||
| David MD, Chief Officer | ||
| Jonathan MD, Chairman CoFounder | ||
| Robert Shoemaker, Senior Research |
Erasca Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Erasca a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 559.59 M | ||||
| Shares Outstanding | 282.73 M | ||||
| Shares Owned By Insiders | 12.39 % | ||||
| Shares Owned By Institutions | 8.00 % | ||||
| Number Of Shares Shorted | 32.15 M | ||||
| Price To Book | 1.83 X | ||||
| EBITDA | (121.31 M) | ||||
| Net Income | (125.04 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.